Showing results (381-390 of 1,188) with videos related to

Sort By:
Pageof 119
European Journal of Haematology|September 20, 2017
Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotypeWei Wang, Mark J Routbort, Zhenya Tang, et al.
Cancer|December 13, 2006
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Niche-level immune evasion in <i>TP53</i> mutant AML residual disease revealed by spatial proteomicsHideaki Mizuno, Yuki Nishida, Andrea Bedoy, et al.
Cancer Research|March 3, 2007
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosisYanis A Boumber, Yutaka Kondo, Xuqi Chen, et al.
International Journal of Antimicrobial Agents|March 1, 2022
Head-to-head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testingAndrés Ceballos-Garzon, Guillermo Garcia-Effron, Susana Cordoba, et al.
Cancer|October 22, 2008
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survivalGautam Borthakur, Hagop Kantarjian, Xuemei Wang, et al.
Revista Argentina De Microbiologia|April 20, 2021
[Usefulness of the Sensititre YeastOne® panel to detect Candida species resistant to antifungal drugs]Susana Córdoba, Claudio Abiega, Iris Agorio, et al.
Leukemia & Lymphoma|December 7, 2020
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experienceRita Assi, Hagop Kantarjian, Michael Keating, et al.
Evolution; International Journal of Organic Evolution|March 10, 2026
Allochronic isolation between sympatric populations of an alpine butterflyChristopher A Halsch, Chris C Nice, Katherine L Bell, et al.
Leukemia & Lymphoma|August 22, 2015
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment responseJie Peng, Robert P Hasserjian, Guilin Tang, et al.
Pageof 119